ReviewFrontiers in reproductive health2026
Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review.
Review in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread use of combination antiretroviral therapy has transformed HIV infection into a chronic condition, with life expectancy of people with HIV (PWH) approaching that of the general population when treatment is initiated early and virological suppression is maintained. As survival has improved, the demographic profile of the HIV population has shifted substantially, with a growing proportion of PWH in high-income countries now aged 50 years and older. In this context, the goals of HIV care extend beyond durable virological suppression to include long-term tolerability, management of multimorbidity, reduction of polypharmacy-related risks, and preservation of functional status and quality of life. Three-drug antiretroviral regimens (3DR) have long represented the standard of care due to their robust efficacy and high genetic barrier to resistance. However, in aging and comorbid PWH, lifelong exposure to multiple antiretroviral agents may increase the risk of cumulative organ toxicity-including renal, bone, and cardiovascular adverse effects-as well as clinically relevant drug-drug interactions with medications used to manage concomitant conditions. These considerations have driven interest in treatment simplification strategies, with dual antiretroviral therapy (2DR) emerging as the most clinically investigated approach. Current international guidelines endorse specific 2DR strategies on the basis of randomized controlled trials demonstrating non-inferior virological efficacy compared with 3DR in carefully selected populations. This narrative review integrates evidence from randomized trials and real-world observational studies to critically appraise the role of guideline-endorsed 2DR vs. 3DR in aging and comorbid PWH. We highlight clinical scenarios in which simplification may be advantageous, identify factors associated with reduced durability, and propose a patient-centred framework to support individualized antiretroviral therapy selection, one that extends beyond virological endpoints to incorporate the geriatric dimensions of contemporary HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.